Integration of Pharmaceutical Discovery and Development

Chapter 1 Introduction

Chapter 2 Renin Inhibitors

Chapter 3 The Discovery and Development of Angiotensin II Antagonists

Chapter 4 Development of an Orally Active Tripeptide Arginal Thrombin Inhibitor

Chapter 5 Discovery and Development of an Endothelin a Receptor-Selective Antagonist PD 156707

Chapter 6 Endothelin Receptor Antagonists

Chapter 7 LHRH Antagonists

Chapter 8 LHRH Agonists

Chapter 9 Discovery and Development of Somatostatin Agonists

Chapter 10 Factors Impacting the Delivery of Therapeutic Levels of Pyrone-Based HIV Protease Inhibitors

Chapter 11 The Integration of Medicinal Chemistry, Drug Metabolism, and Pharmaceutical Research and Development in Drug Discovery and Development

Chapter 12 De Novo Design and Discovery of Cyclic HIV Protease Inhibitors Capable of Displacing the Active-Site Structural Water Molecule

Chapter 13 Discovery and Development of the BHAP Nonnucleoside Reverse Transcriptase Inhibitor Delavirdine Mesylate

Chapter 14 Famciclovir

Chapter 15 The Use of Esters as Prodrugs for Oral Delivery of β-Lactam Antibiotics

Chapter 16 Hematoregulators

Chapter 17 Discovery and Development of GG745, a Potent Inhibitor of Both Isozymes of of 5α-Reductase

Chapter 18 Discovery of a Potent and Selective α 1A Antagonist

Chapter 19 Discovery of Bioavailable Inhibitors of Secretory Phospholipase A 2

Chapter 20 The Anxieties of Drug Discovery and Development

Chapter 21 CI-1015

Chapter 22 Orally Active Nonpeptide CCK-A Agonists

Chapter 23 Orally Active Growth Hormone Secretagogues

Chapter 24 Dorzolamide, a 40-Year Wait

Chapter 25 Discovery and Development of Novel Melanogenic Drugs